MARK2 and neurodegenerative disease: As mentioned, vorapaxar inhibits all signaling downstream of PAR1, and perhaps the resulting lack of beneficial PAR1 signaling at the BBB or in the nervous system increases the relatively rare risk of ALS, suggesting that therapies that increase beneficial PAR1 signaling could be useful for the prevention or treatment of ALS and other neurodegenerative diseases.